Login / Signup
Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis.
Paige Kingston
Andrew Blauvelt
Bruce Strober
April W Armstrong
Published in:
Journal of psoriasis and psoriatic arthritis (2023)
Deucravacitinib is an effective, safe, and well-tolerated novel oral medication for adults with moderate-to-severe plaque psoriasis.
Keyphrases
</>
high intensity
early onset
coronary artery disease
drug induced
emergency department
combination therapy
adverse drug